Aurinia Pharmaceuticals Inc. (AUPH)

5.53 +0.07 (+1.28%) At close: 04:00PM EDT

Aurinia Pharmaceuticals Inc.

118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 300

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Corporate governance

Aurinia Pharmaceuticals Inc.’s ISS governance QualityScore as of 1 June 2024 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 2; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.